WITHDRAWN: Poly(caprolactone)-b-Poly(ethylene glycol)-based Polymeric Micelles as Drug Carrier for Efficient Breast Cancer Therapy: A Systematic Review

Abstract

Recently, drug delivery systems based on nanoparticles for cancer treatment have become the centre of attention for researchers to design and fabricate drug carriers for anticancer drugs due to the conventional pharmaceuticals lacking tumour-targeting activity. Poly(caprolactone)- b -poly(ethylene glycol) (PCL-PEG)-based micelles have attracted significant attention as a potential drug carrier intended for human use. Since their first discovery, the Food and Drug Administration (FDA)-approved polymers have been studied extensively for various biomedical applications, specifically cancer therapy. The application of PCL-PEG micelles in different cancer therapy has been recorded in countless research for their efficacy as drug cargos. However, systematic studies on the effectiveness of PCL-PEG micelles of specific cancer for pharmaceutical applications are still lacking. As breast cancer is reported as the most prevalent cancer worldwide, we aim to systematically review all available literature that publishes research findings on the PCL-PEG-based micelles as drug cargo for the therapy. We further discussed the preparation method and the anti-tumour efficacy of the micelles. Using prearranged search string, Scopus and Science Direct were selected as the database for the systematic searching strategy. Only eight of the 314 articles met the inclusion requirements and were used for data synthesis. From the review, all studies reported the efficiency of PCL-PEG-based micelles, which act as drug cargo for breast cancer therapy.